Bedford, Massachusetts-based Lantheus Holdings, Inc. has been making strides in the development, manufacturing, and commercialization of diagnostic and therapeutic products aimed at assisting clinicians worldwide in the identification and treatment of heart, cancer, and other diseases. Its portfolio includes ultrasound enhancing agent DEFINITY, technetium generator TechneLite, pulmonary function-assessing Xenon-133, brain blood flow identifier Neurolite, and Tc-99m-labeled imaging agent Cardiolite. The company also offers several other therapies, including radiotherapeutic therapy AZEDRA, Automated Bone Scan Index, RELISTOR, and PYLARIFY. Lantheus Holdings, Inc. continues to produce innovative products such as flurpiridaz, an assessment tool for blood flow to the heart and PNT2002 for pre-chemotherapy patients. The company has partnered with notable firms, including Bausch Health Companies, Inc., GE Healthcare Limited, and FUJIFILM.